Role of copper in human neurological disorders

American Journal of Clinical Nutrition

Volumn 88, Issue 3, 2008, Pages

  Desai, Vishal ^a   Kaler, Stephen G ^a,b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b MSC 1832 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COPPER; FREE RADICAL; TRACE ELEMENT;

ACERULOPLASMINEMIA; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CENTRAL NERVOUS SYSTEM; CONFERENCE PAPER; DNA STRAND BREAKAGE; HUNTINGTON CHOREA; MENKES SYNDROME; METABOLIC DISORDER; NERVE CELL LESION; NERVOUS SYSTEM DEVELOPMENT; NEUROLOGIC DISEASE; OCCIPITAL HORN SYNDROME; PHENOTYPE; PRION DISEASE;

EID: 51749108879     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/88.3.855s     Document Type: Conference Paper

References (41)

1. Cox DW, Moore SDP. Copper transporting P-type ATPases and human disease. J Bioenerg Biomembr 2002;34:333-8.
2. Madsen E, Gitlin JD. Copper and iron disorders of the brain. Annu Rev Neurosci 2007;30:317-37.
3. Zucconi GG, Cipriani S, Scattoni R, Balgkouranidou I, Hawkins DP, Ragnarsdottir KV. Copper deficiency elicits glial and neuronal response typical of neurodegenerative disorders. Neuropathol Appl Neurobiol 2007;33:212-25.
4. Rinaldi AC. Meeting report: copper research at the top. Biometals 2000;13:9-13.
5. Kaler SG. Metabolic and molecular bases of Menkes disease and occipital horn syndrome. Pediatr Dev Pathol 1998;1:85-98.
6. Waggoner DJ, Bartnikas TB, Gitlin JD. The role of copper in neurodegenerative disease. 1999;6:221-30.
7. Harris ZL, Klomp LWJ, Gitlin JD. Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. Am J Clin Nutr 1998;67:972-7.
8. Hofmann WP, Welsch C, Takahashi Y, et al. Identification and in silico characterization of a novel compound heterozygosity associated with hereditary aceruloplasminemia. Scand J Gastroenterol 2007;42:1088-94.
9. Roos PM, Vesterberg O, Nordberg M. Metals in motor neuron diseases. Exp Biol Med 2006;231:1481-7.
10. Lutsenko S, Barnes NL, Bartee MY, Dmitriev OY. Function and regulation of human copper-transporting ATPases. Physiol Rev 2007;87:1011-46.
11. Taylor JP, Hardy J, Fischbeck KH. Toxic proteins in neurodegenerative disease. Science Mag 2002;296:1991-5.
12. Dingwall C. A copper-binding site in the cytoplasmic domain or BACE1 identifies a possible link to metal homeostasis and oxidative stress in Alzheimer's disease. Biochem Soc Trans 2007;35:571-3.
13. Ha C, Ryu J, Park CB. Metal ions differentially influence the aggregation of deposition of Alzheimer's β-amyloid on a solid template. Biochemistry 2007;46:6118-25.
14. Wantabe S, Nagano S, Duce J, et al. Increased affinity for copper mediated by cysteine 111 in forms of mutant superoxide dismutase 1 linked to amyotrophic lateral sclerosis. Free Radic Biol Med 2007;42:1534-42.
15. Fox JH, Kama JA, Lieberman G, et al. Mechanisms of copper ion mediated Huntington's disease progression. PLoS ONE 2007;2:e334.
16. Liu P-C, McAndrew PE, Kaler SG. Rapid and robust screening of the Menkes disease/occipital horn syndrome gene. Genetic Testing 2002;6:255-60.
17. Kaler SG, Buist NRM, Holmes CS, Goldstein DS, Miller RC, Gahl WA. Early copper therapy in classic Menkes disease patients with a novel splicing mutation. Ann Neurol 1995;38:921-8.
18. Kaler SG, Das S, Levinson B, et al. Successful early copper therapy in Menkes disease associated with a mutant transcript containing a small in-frame deletion. Biochem Mol Med 1996;57:37-46.
19. Kaler SG. Menkes disease mutations and response to early copper histidine treatment. Nat Genet 1996;13:21-2.
20. Liu PC, Chen YW, Centano J, Quesado M, Lem KE, Kaler SG. Downregulation of myelination, energy, and translational genes in Menkes disease brain. Mol Genet Metab 2005;85:291-300.
21. Kaler SG, Holmes CS, Goldstein DS, et al. Neonatal diagnosis and treatment of Menkes disease. N Engl J Med 2008;358:605-14.
22. Kumar N, Elliott MA, Hoyer JD, Harper CM, Ahlskog JE, Phyliky RL. Myelodysplasia, myeloneuropathy, and copper deficiency. Mayo Clin Proc 2005;80:943-6.
23. Kaler SG, Gallo LK, Proud VK, et al. Occipital horn syndrome and a mild Menkes phenotype associated with splice site mutations at the MNK locus. Nat Genet 1994;8:195-202.
24. Tang J, Robertson SP, Lem KE, Godwin SC, Kaler SG. Functional copper transport explains neurologic sparing in occipital horn syndrome. Genet Med 2006;8:711-8.
25. Kaler SG. Menkes disease. In: Robertson D, Low PA, Burnstock G, Biaggioni I, eds. Primer on the autonomic nervous system. 2nd edition. San Diego, CA: Academic Press, 2004:277-9.
26. McCorry LK. Physiology of the autonomic nervous system. Am J Pharm Educ 2007;71:78.
27. Gaggelli E, Kozlowski H, Valensin D, Valensin G. Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis). Chem Rev 2006;106:1995-2044.
28. Rasia RM, Bertoncini CW, Marsh D, et al. Structural characterization of copper(II) binding to alpha-synuclein: insights into the bioinorganic chemistry of Parkinson's disease. Proc Natl Acad Sci U S A 2005;102:4294-9.
29. Watts JC, Westaway D. The prion protein family: diversity, rivalry, and dysfunction. Biochim Biophys Acta 2007;1772:654-72.
30. Watts JC, Balachandran A, Westaway D. The expanding universe of prion diseases. PLoS Pathog 2006;2:e26.
31. Scheinberg H, Sternlieb I. Wilson's disease. Major problems in internal medicine. v. 23. Philadelphia, PA: WB Saunders Company, 1984.
32. Kaler SG. Wilson disease. In: Goldman L, Ausiello D, eds. Cecil's textbook of medicine. 23rd ed. Chapter 230. Philadelphia, PA: Saunders (in press).
33. Matsuo M, Tasaki R, Kodama H, Hamasaki Y. Screening for Menkes disease using the urine HVA/VMA ratio. J Inherit Metab Dis 2005;28:89-93.
34. Danzeisen R, Araya M, Harrison B, et al. How reliable and robust are current biomarkers for copper status? Br J Nutr 2007;98:676-83.
35. Suazo M, Olivares F, Mendez MA, et al. CCS and SOD1 mRNA are reduced after copper supplementation in peripheral mononuclear cells of individuals with high serum ceruloplasmin concentration. J Nutr Biochem 2008;19:269-74.
36. Cobine PA, Pierrel F, Winge DR. Copper trafficking to the mitochondrion and assembly of copper metalloenzymes. Biochim Biophys Acta 2006;1763:759-72.
37. El Meskini R, Culotta VC, Mains RE, Eipper BA. Supplying copper to the cuproenzyme peptidylglycine alpha-amidating monooxygenase. J Biol Chem 2003;278:12278-84.
38. Hardman B, Michalczyk A, Greenough M, Camakaris J, Mercer J, Ackland L. Distinct functional roles for the Menkes and Wilson copper translocating P-type ATPases in human placental cells. Cell Physiol Biochem 2007;20:1073-84.
39. Muñoz C, López M, Olivares M, Pizarro F, Arredondo M, Araya M. Differential response of interleukin-2 production to chronic copper supplementation in healthy humans. Eur Cytokine Netw 2005;16:261-5.
40. 2+ binding-induced destabilization of beta2-microglobulin revealed by molecular dynamics simulation. Biophys J 2006;90:3865-79.
41. Ikeda M, Ohashi F, Fukui Y, Takada S, Moriguchi J, Ezaki T. Changes in tubular dysfunction marker levels in parallel with the levels of copper, rather than cadmium, in urine of middle-aged women in non-polluted areas. Int Arch Occup Environ Health 2007;80:171-83.